Currently, financial markets are experiencing a mix of optimism and caution as investors react to changing economic ...

Most U.S. states do not currently cover highly sought after weight-loss drugs from Novo Nordisk and Eli Lilly in their ...

Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and ...

While all state Medicaid programs cover GLP-1 agonists for type 2 diabetes, it’s much less common for them to cover the drugs ...

Despite the benefits of such medicines, like Wegovy, Saxenda and Zepbound, many people who could most benefit from them can’t ...

Currently, financial markets are experiencing a mix of optimism and caution as investors react to changing economic ...

The retrospective study points to fewer suicidal thoughts or attempts among adolescents taking semaglutide or liraglutide.

Amid ongoing legal battles over coveted GLP-1 therapies, a drug vendor in Washington state is accused of running an ...

Structure Therapeutics has the potential to have a best-in-class GLP-1 agonist drug for treatment of patients with obesity. Learn more on GPCR stock here.

If you’ve listened to any weight-loss podcasts or watched the news in the past year, you’ve probably heard of the new drugs: ...

Research hints that medications like Zepbound and Wegovy could provide new ways to treat opioid and alcohol abuse.